Market Research Report

Ankylosing Spondylitis Therapeutics - Pipeline Assessment and Market Forecasts to 2019
cover Published by GlobalData
Published Product code 230840
Content info Pages: 71
Price

Introduction

Abstract

Ankylosing Spondylitis Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Summary

GlobalData, the industry analysis specialist, has released its new report, "Ankylosing Spondylitis Therapeutics - Pipeline Assessment and Market Forecasts to 2019". The report is an essential source of information and analysis on the global Ankylosing Spondylitis Therapeutics market. The report identifies the key trends shaping and driving the global Ankylosing Spondylitis Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Ankylosing Spondylitis Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Ankylosing Spondylitis Therapeutics market. Its scope includes -

  • Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Ankylosing Spondylitis Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.
  • Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
  • Analysis of the current and future competition in the seven key countries Ankylosing Spondylitis Therapeutics market.
  • Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Ankylosing Spondylitis Therapeutics market.
  • Analysis of key recent licensing and partnership agreements in Ankylosing Spondylitis Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global Ankylosing Spondylitis Therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Ankylosing Spondylitis Therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
  • What's the next big thing in the global Ankylosing Spondylitis Therapeutics market landscape? - Identify, understand and capitalize.

Table of Contents

TOC

1 Table of Contents

1 Table of Contents 3

  • 1.1 List of Tables 5
  • 1.2 List of Figures 6

2 Ankylosing Spondylitis Therapeutics - Introduction 7

  • 2.1 Disease Overview 7
  • 2.2 Epidemiology 7
    • 2.2.1 Prevalence 7
    • 2.2.2 Ethnicity 8
    • 2.2.3 Gender 8
    • 2.2.4 Quality of Life Parameters 9
    • 2.2.5 Socioeconomic Impact 9
    • 2.2.6 Mortality and Morbidity 9
  • 2.3 Etiology and Pathology 9
  • 2.4 Signs and Symptoms 10
  • 2.5 Diagnosis 10

2.5.1 Patient History 10

    • 2.5.2 Physical Examination 10
    • 2.5.3 Laboratory Tests 11
    • 2.5.4 Imaging Tests 11
    • 2.5.5 Modified New York Criteria 12
  • 2.6 Treatment and Management Options 12
    • 2.6.1 Medications 12
    • 2.6.2 Exercise and Physiotherapy 15
    • 2.6.3 Surgery 15
  • 2.7 Referral Pathway 15
  • 2.8 GlobalData Pipeline Report Guidance 16

3 Ankylosing Spondylitis Therapeutics - Market Characterization 17

  • 3.1 Overview 17
  • 3.2 Ankylosing Spondylitis Therapeutics Market Size (2006-2011) - Global 17
  • 3.3 Ankylosing Spondylitis Therapeutics Market Forecast (2011-2019) - Global 18
  • 3.4 Ankylosing Spondylitis Therapeutics Market Size (2006-2011) - The US 19
  • 3.5 Ankylosing Spondylitis Therapeutics Market Forecast (2011-2019) - The US 20
  • 3.6 Ankylosing Spondylitis Therapeutics Market Size (2006-2011) - France 21
  • 3.7 Ankylosing Spondylitis Therapeutics Market Forecast (2011-2019) - France 22
  • 3.8 Ankylosing Spondylitis Therapeutics Market Size (2006-2011) - Germany 23
  • 3.9 Ankylosing Spondylitis Therapeutics Market Forecast (2011-2019) - Germany 24
  • 3.10 Ankylosing Spondylitis Therapeutics Market Size (2006-2011) - Italy 25
  • 3.11 Ankylosing Spondylitis Therapeutics Market Forecast (2011-2019) - Italy 26
  • 3.12 Ankylosing Spondylitis Therapeutics Market Size (2006-2011) - Spain 27
  • 3.13 Ankylosing Spondylitis Therapeutics Market Forecast (2011-2019) - Spain 28
  • 3.14 Ankylosing Spondylitis Therapeutics Market Size (2006-2011) - The UK 29
  • 3.15 Ankylosing Spondylitis Therapeutics Market Forecast (2011-2019) - The UK 30
  • 3.16 Ankylosing Spondylitis Therapeutics Market Size (2006-2011) - Japan 31
  • 3.17 Ankylosing Spondylitis Therapeutics Market Forecast (2011-2019) - Japan 32
  • 3.18 Drivers and Barriers for the Ankylosing Spondylitis Therapeutics Market 33
    • 3.18.1 Drivers for the Ankylosing Spondylitis Therapeutics Market 33
    • 3.18.2 Barriers for the Ankylosing Spondylitis Therapeutics Market 33
  • 3.19 Opportunity and Unmet Need Analysis 34
  • 3.20 Key Takeaway 34

4 Ankylosing Spondylitis Therapeutics - Competitive Assessment 35

  • 4.1 Overview 35
  • 4.2 Strategic Competitor Assessment 35
  • 4.3 Product Profiles for the Major Marketed Products in the Ankylosing Spondylitis Market 36
    • 4.3.1 Celebrex (celecoxib) 36
    • 4.3.2 Arcoxia (etoricoxib) 37
    • 4.3.3 Enbrel (etanercept) 38
    • 4.3.4 Humira (adalimumab) 39
    • 4.3.5 Remicade (infliximab) 41
    • 4.3.6 Simponi (golimumab) 43
  • 4.4 Key Takeaway 45

5 Ankylosing Spondylitis Therapeutics - Pipeline Assessment 46

  • 5.1 Overview 46
  • 5.2 Strategic Pipeline Assessment 46
  • 5.3 Ankylosing Spondylitis Therapeutics Pipeline - Pipeline by Phases of Development 46
    • 5.3.1 Ankylosing Spondylitis Therapeutics - Phase III Pipeline 47
    • 5.3.2 Ankylosing Spondylitis Therapeutics - Phase II Pipeline 47
    • 5.3.3 Ankylosing Spondylitis Therapeutics - Phase I Pipeline 47
    • 5.3.4 Ankylosing Spondylitis Market - Pre-Clinical Pipeline 48
  • 5.4 Ankylosing Spondylitis Therapeutics Market - Pipeline by Mechanism of Action 48
  • 5.5 Technology Trends Analytic Framework 49
  • 5.6 Ankylosing Spondylitis Therapeutics - Promising Drugs Under Development 50
  • 5.7 Molecule Profile for Promising Drugs under Development 50
    • 5.7.1 AIN457 (secukinumab) 50
    • 5.7.2 Cimzia (certolizumab pegol) 51
  • 5.8 Key Takeaway 51

6 Ankylosing Spondylitis Therapeutics - Clinical Trials Mapping 52

  • 6.1 Clinical Trials by Region/Country (the US, EU5 and Japan) 52
  • 6.2 Clinical Trials by Phase 53
  • 6.3 Clinical Trials by Trial Status 54
  • 6.4 Prominent Sponsors 55
  • 6.5 Top Companies Participating in Ankylosing Spondylitis Therapeutics Clinical Trials 57

7 Ankylosing Spondylitis Therapeutics - Strategic Assessment 58

  • 7.1 Key Events Impacting the Future Market 58
  • 7.2 Ankylosing Spondylitis Therapeutics: Implications for Future Market Competition 59

8 Ankylosing Spondylitis Therapeutics - Future Players 60

  • 8.1 Introduction 60
  • 8.2 Company Profiles 60
    • 8.2.1 Novartis 60
    • 8.2.2 UCB 63

9 Licensing and Partnership Deals 64

10 Ankylosing Spondylitis Therapeutics - Appendix 65

  • 10.1 Market Definitions 65
  • 10.2 Abbreviations 65
  • 10.3 Methodology 66
    • 10.3.1 Coverage 66
    • 10.3.2 Secondary Research 67
    • 10.3.3 Forecasting 67
    • 10.3.4 Primary Research 69
    • 10.3.5 Expert Panel Validation 70
  • 10.4 Contact Us 70
  • 10.5 Disclaimer 70
  • 10.6 Bibliography 70

List of Tables

1.1 List of Tables

  • Table 1: Prevalence of Ankylosing Spondylitis in Different Ethnic Groups and Regions 8
  • Table 2: Ankylosing Spondylitis Therapeutics Market, Global, Revenue ($m), 2006-2011 17
  • Table 3: Ankylosing Spondylitis Therapeutics Market, Global, Forecast ($m), 2011-2019 18
  • Table 4: Ankylosing Spondylitis Therapeutics Market, The US, Revenue ($m), 2006-2011 19
  • Table 5: Ankylosing Spondylitis Therapeutics Market, The US, Forecast ($m), 2011-2019 20
  • Table 6: Ankylosing Spondylitis Therapeutics Market, France, Revenue ($m), 2006-2011 21
  • Table 7: Ankylosing Spondylitis Therapeutics Market, France, Forecast ($m), 2011-2019 22
  • Table 8: Ankylosing Spondylitis Therapeutics Market, Germany, Revenue ($m), 2006-2011 23
  • Table 9: Ankylosing Spondylitis Therapeutics Market, Germany, Forecast ($m), 2011-2019 24
  • Table 10: Ankylosing Spondylitis Therapeutics Market, Italy, Revenue ($m), 2006-2011 25
  • Table 11: Ankylosing Spondylitis Therapeutics Market, Italy, Forecast ($m), 2011-2019 26
  • Table 12: Ankylosing Spondylitis Therapeutics Market, Spain, Revenue ($m), 2006-2011 27
  • Table 13: Ankylosing Spondylitis Therapeutics Market, Spain, Forecast ($m), 2011-2019 28
  • Table 14: Ankylosing Spondylitis Therapeutics Market, The UK, Revenue ($m), 2006-2011 29
  • Table 15: Ankylosing Spondylitis Therapeutics Market, The UK, Forecast ($m), 2011-2019 30
  • Table 16: Ankylosing Spondylitis Therapeutics Market, Japan, Revenue ($m), 2006-2011 31
  • Table 17: Ankylosing Spondylitis Therapeutics Market, Japan, Forecast ($m), 2011-2019 32
  • Table 18: Components of Ankylosing Spondylitis Disease Activity 38
  • Table 19: Components of Ankylosing Spondylitis Disease Activity 40
  • Table 20: Components of Ankylosing Spondylitis Disease Activity 42
  • Table 21: Proportion of ASAS Responders at Weeks 14 and 24 43
  • Table 22: Median Percent Improvement in ASAS Components AT Week 14 44
  • Table 23: Ankylosing Spondylitis Therapeutics, Phase III Pipeline, 2011 47
  • Table 24: Ankylosing Spondylitis Therapeutics, Phase II Pipeline, 2011 47
  • Table 25: Ankylosing Spondylitis Therapeutics, Phase I Pipeline, 2011 47
  • Table 26: Ankylosing Spondylitis Therapeutics, Pre-Clinical Pipeline, 2011 48
  • Table 27: Ankylosing Spondylitis Therapeutics - Most Promising Drugs Under Development, 2011 50
  • Table 28: Ankylosing Spondylitis Therapeutics, Clinical Trials by Country, 2011 52
  • Table 29: Ankylosing Spondylitis Therapeutics, Clinical Trials by Phase, 2011 53
  • Table 30: Ankylosing Spondylitis Therapeutics, Clinical Trials by Status of Development, 2011 54
  • Table 31: Ankylosing Spondylitis Therapeutics, Prominent Sponsors, 2011 56
  • Table 32: Ankylosing Spondylitis Therapeutics, Top Companies Participating in Therapeutics Clinical Trials, 2011 57
  • Table 33: Novartis - Inflammation and Immunology Pipeline, 2011 62
  • Table 34: Novartis - Ankylosing Spondylitis Pipeline, 2011 62
  • Table 35: UCB - Immunology Pipeline, 2011 63
  • Table 36: UCB- Ankylosing Spondylitis Pipeline, 2011 63
  • Table 37: Ankylosing Spondylitis Therapeutics, Global, Deals, 2009-2011 64

List of Figures

1.2 List of Figures

  • Figure 1: Ankylosing Spondylitis 7
  • Figure 2: Pathogenesis of Ankylosing Spondylitis 10
  • Figure 3: Modified New York Criteria 12
  • Figure 4: Comparisons of NSAIDs 13
  • Figure 5: Comparisons of DMARDs 13
  • Figure 6: Comparisons of Corticosteroids 14
  • Figure 7: Comparisons of Biologics 14
  • Figure 8: Ankylosing Spondylitis Therapeutics - Referral Pathway 15
  • Figure 9: Ankylosing Spondylitis Therapeutics Market, Global, Revenue ($m), 2006-2011 17
  • Figure 10: Ankylosing Spondylitis Therapeutics Market, Global, Forecast ($m), 2011-2019 18
  • Figure 11: Ankylosing Spondylitis Therapeutics Market, The US, Revenue ($m), 2006-2011 19
  • Figure 12: Ankylosing Spondylitis Therapeutics Market, The US, Forecast ($m), 2011-2019 20
  • Figure 13: Ankylosing Spondylitis Therapeutics Market, France, Revenue ($m), 2006-2011 21
  • Figure 14: Ankylosing Spondylitis Therapeutics Market, France, Forecast ($m), 2011-2019 22
  • Figure 15: Ankylosing Spondylitis Therapeutics Market, Germany, Revenue ($m), 2006-2011 23
  • Figure 16: Ankylosing Spondylitis Therapeutics Market, Germany, Forecast ($m), 2011-2019 24
  • Figure 17: Ankylosing Spondylitis Therapeutics Market, Italy, Revenue ($m), 2006-2011 25
  • Figure 18: Ankylosing Spondylitis Therapeutics Market, Italy, Forecast ($m), 2011-2019 26
  • Figure 19: Ankylosing Spondylitis Therapeutics Market, Spain, Revenue ($m), 2006-2011 27
  • Figure 20: Ankylosing Spondylitis Therapeutics Market, Spain, Forecast ($m), 2011-2019 28
  • Figure 21: Ankylosing Spondylitis Therapeutics Market, The UK, Revenue ($m), 2006-2011 29
  • Figure 22: Ankylosing Spondylitis Therapeutics Market, The UK, Forecast ($m), 2011-2019 30
  • Figure 23: Ankylosing Spondylitis Therapeutics Market, Japan, Revenue ($m), 2006-2011 31
  • Figure 24: Ankylosing Spondylitis Therapeutics Market, Japan, Forecast ($m), 2011-2019 32
  • Figure 25: Opportunity and Unmet Need in the Ankylosing Spondylitis Therapeutics Market, 2011 34
  • Figure 26: Ankylosing Spondylitis Therapeutics, Strategic Competitor Assessment, 2011 36
  • Figure 27: Ankylosing Spondylitis Therapeutics - Pipeline by Phase of Development, 2011 46
  • Figure 28: Ankylosing Spondylitis Therapeutics, Pipeline by Mechanism of Action (%), 2011 48
  • Figure 29: Ankylosing Spondylitis Therapeutics, Technology Trends Analytics Framework, 2011 49
  • Figure 30: Ankylosing Spondylitis Therapeutics, Technology Trends Analytics Framework, Description, 2011 50
  • Figure 31: Ankylosing Spondylitis Therapeutics, Clinical Trials by Country, 2011 52
  • Figure 32: Ankylosing Spondylitis Therapeutics, Clinical Trials by Phase (%), 2011 53
  • Figure 33: Ankylosing Spondylitis Therapeutics, Clinical Trials by Status of Development (%), 2011 54
  • Figure 34: Ankylosing Spondylitis Therapeutics, Overall Sponsors (%), 2011 55
  • Figure 35: Ankylosing Spondylitis Therapeutics, Prominent Sponsors (%), 2011 56
  • Figure 36: Ankylosing Spondylitis Therapeutics, Top Companies Participating in Clinical Trials, 2011 57
  • Figure 37: Ankylosing Spondylitis Therapeutics Market, Drivers and Restraints, 2011 58
  • Figure 38: Implications for Future Market Competition in the Ankylosing Spondylitis Market, 2011 59
  • Figure 39: Ankylosing Spondylitis Therapeutics Market, Pipeline by Company, 2011 60
  • Figure 40: GlobalData Market Forecasting Model 69

Ankylosing Spondylitis Therapeutics - Pipeline Assessment and Market Forecasts to 2019 published by GlobalData in January 27, 2012. This report consists of Pages: 71 and the price starts from US $ 3995.

Back to Top